Moderna and Samsung Biologics announced a manufacturing services and supply agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine.
Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics’ facilities in Incheon, South Korea, for the production of hundreds of millions of doses of Moderna’s COVID-19 vaccine intended for the supply of markets outside of the US starting in the third quarter of 2021.
John Rim, CEO of Samsung Biologics said, “Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.”
“We are pleased to partner with Samsung Biologics for this fill and finish manufacturing, which will help us continue to scale up our manufacturing capacity outside of the US,” said Juan Andres, Moderna’s Chief Technical Operations and Quality Officer.